Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Route 92 Medical Announces the 100th Patent for its Neurovascular Intervention Portfolio

SAN MATEO, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the company’s 100th global issued patent for its innovative neurovascular intervention product portfolio. The company offers a range of solutions for neurovascular interventional procedures including its FreeClimb Catheter Systems and Monopoint® Operating Platform, both powered by its Tenzing® Delivery Catheter.

“Our FreeClimb and HiPoint catheters work as a system with our Tenzing delivery paradigm. Collectively, these solutions work harmoniously as part of our Monopoint Operating Platform to enhance procedural efficiency and enable the delivery of large-bore and super-bore catheters without a microcatheter and with reduced use of a guidewire,” said John Miller, Chief Technology Officer at Route 92 Medical and medical device veteran with over 20 years of neurovascular innovation experience dating back to the earliest stroke intervention devices. “The ability of this technology to simplify stroke treatment is unique. This technology is designed to streamline the procedure, creating single-operator control over all elements, with the goal of reducing procedure time and cost while improving patient outcomes.”

“Route 92 has reinvented neurovascular intervention and will vigorously defend our intellectual property, which underlies our ability to continue to develop new solutions for arterial and venous access and treatment in the brain,” said Tony Chou, Chief Executive Officer and Founder at Route 92 Medical. “In 2024, we plan to continue to build the evidence base to support the clinical adoption of our stroke solutions. We will also focus on growing our product portfolio and improving operational effectiveness to enable us to scale our business for commercial success.”

Route 92 Medical’s first step in revolutionizing neurovascular intervention is focused on acute ischemic stroke. The company will be launching a range of reperfusion systems that utilize innovative designs, including the Tenzing® delivery catheter. These cutting-edge products are intricately designed to function seamlessly as a comprehensive system, enhancing the effectiveness of endovascular thrombectomy procedures. This, in turn, empowers healthcare professionals to swiftly restore blood flow to a patient's brain after an acute ischemic stroke, the prevailing type of stroke affecting patients today.

Route 92 Medical has a global intellectual property position with strong protection for its inventions in key markets including the U.S., Europe, and China. The company's patent portfolio is growing rapidly with eight patents issued in 2023, including patents with claims across the company’s Monopoint® portfolio, including its Tenzing® and HiPoint™ catheter devices.

About Route 92 Medical, Inc.

Route 92 Medical is on a mission to improve outcomes for patients undergoing neurovascular intervention through cutting-edge engineering and innovative product design. Founded by physicians, the company collaborates with leading neurovascular clinicians to solve the biggest challenges in neurointervention and deliver meaningful, differentiated solutions that promote clinical success. For more information, visit www.r92m.com or follow the company on LinkedIn.


Contacts:

For media:
Gwen Gordon
Gwen Gordon PR
Gwen@gwengordonpr.com

Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.